Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition (NCT06218628)
Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) Inhibition
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Who can join: Review the eligibility criteria below.
Location: Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 728-2451
Email: abigail.okeefe@fccc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Myelofibrosis
- CINC424A2X01B Rollover Protocol — Darlinghurst, New South Wales
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk — Los Angeles, California
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — Seattle, Washington
- Study of Canakinumab in Patients With Myelofibrosis — Los Angeles, California
- Decitabine in Treating Patients With Myelofibrosis — Chicago, Illinois
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Birmingham, Alabama
Explore by condition: All Primary Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.